home / stock / fgen / fgen short
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,739,119 |
Total Actual Volume | 14,095,252 |
Short Trends | |
---|---|
Cover Days | 4 |
Short Days | 14 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 86,956 |
Average Short Percentage | 54.82% |
Is there a FGEN Short Squeeze or Breakout about to happen?
See the FGEN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Stock Date | Open Price | Close Price | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
2022-08-17 | 14.26 | 12.76 | 14.51 | 14.16 | 514,440 | 74,671 | 76.3804 |
2022-08-16 | 14.5 | 12.76 | 14.56 | 14.2 | 519,243 | 54,040 | 29.0233 |
2022-08-15 | 14.36 | 12.76 | 14.77 | 14.35 | 424,401 | 67,107 | 78.2251 |
2022-08-11 | 14.5 | 12.76 | 14.64 | 13.87 | 743,267 | 146,665 | 64.7839 |
2022-08-10 | 14.62 | 12.76 | 14.62 | 14.24 | 677,434 | 89,428 | 52.4329 |
2022-08-09 | 13.42 | 12.76 | 14.36 | 13.31 | 916,353 | 241,416 | 79.1154 |
2022-08-08 | 14.53 | 12.76 | 14.65 | 14.05 | 516,519 | 56,187 | 53.6361 |
2022-08-04 | 12.77 | 12.76 | 14.04 | 12.77 | 817,482 | 64,015 | 25.1661 |
2022-08-03 | 12.59 | 12.76 | 13.26 | 12.53 | 1,048,766 | 87,292 | 39.6490 |
2022-08-02 | 12.11 | 12.76 | 12.4 | 12.0672 | 344,891 | 53,758 | 72.0047 |
2022-08-01 | 12.43 | 12.76 | 12.82 | 12.06 | 520,917 | 36,715 | 57.9183 |
2022-07-29 | 12.88 | 12.76 | 12.88 | 12.53 | 849,235 | 166,686 | 80.5281 |
2022-07-28 | 12.76 | 12.76 | 13.1 | 12.37 | 601,604 | 86,599 | 66.2513 |
2022-07-26 | 12.12 | 12.12 | 12.73 | 12.08 | 104,060 | 57,712 | 53.3388 |
2022-07-25 | 12.3 | 12.19 | 12.3 | 11.93 | 707,227 | 57,323 | 62.6604 |
2022-07-19 | 12.19 | 12.49 | 12.8498 | 12.19 | 838,212 | 43,970 | 14.5990 |
2022-07-18 | 12.22 | 12.09 | 12.66 | 11.99 | 971,346 | 86,335 | 46.8263 |
2022-07-15 | 12.28 | 12.22 | 12.36 | 11.97 | 1,190,774 | 114,444 | 66.9142 |
2022-07-14 | 12.38 | 12 | 12.38 | 11.85 | 835,799 | 102,031 | 62.5278 |
2022-07-13 | 11.76 | 12.47 | 12.5 | 11.71 | 953,282 | 52,725 | 14.3848 |
News, Short Squeeze, Breakout and More Instantly...
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 Continued significant roxadustat volume growth in China SAN F...
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & F...
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment comm...